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ABSTRACT
Objective To examine mortality and morbidity patterns 
before and after premalignancy diagnosis in individuals 
with monoclonal gammopathy of undetermined 
significance (MGUS) and monoclonal B- cell lymphocytosis 
(MBL) and compare their secondary healthcare activity to 
that of the general population.
Design Population- based patient cohort, within which 
each patient is matched at diagnosis to 10 age- matched 
and sex- matched individuals from the general population. 
Both cohorts are linked to nationwide information 
on deaths, cancer registrations and Hospital Episode 
Statistics.
Setting The UK’s Haematological Malignancy Research 
Network, which has a catchment population of around 4 
million served by 14 hospitals and a central diagnostic 
laboratory.
Participants All patients newly diagnosed during 2009–
2015 with MGUS (n=2193) or MBL (n=561) and their age 
and sex- matched comparators (n=27 538).
Main outcome measures Mortality and hospital inpatient 
and outpatient activity in the 5 years before and 3 years 
after diagnosis.
Results Individuals with MGUS experienced excess 
morbidity in the 5 years before diagnosis and excess 
mortality and morbidity in the 3 years after diagnosis. 
Increased rate ratios (RRs) were evident for nearly all 
clinical specialties, the largest, both before and after 
diagnosis, being for nephrology (before RR=4.29, 95% 
CI 3.90 to 4.71; after RR=13.8, 95% CI 12.8 to 15.0) and 
rheumatology (before RR=3.40, 95% CI 3.18 to 3.63; after 
RR=5.44, 95% CI 5.08 to 5.83). Strong effects were also 
evident for endocrinology, neurology, dermatology and 
respiratory medicine. Conversely, only marginal increases 
in mortality and morbidity were evident for MBL.
Conclusions MGUS and MBL are generally considered 
to be relatively benign, since most individuals with 
monoclonal immunoglobulins never develop a B- cell 
malignancy or any other monoclonal protein- related 
organ/tissue- related disorder. Nonetheless, our findings 
offer strong support for the view that in some individuals, 
monoclonal gammopathy has the potential to cause 
systemic disease resulting in wide- ranging organ/tissue 
damage and excess mortality.
BACKGROUND
Monoclonal gammopathy of undetermined 
significance (MGUS) and monoclonal B- cell 
lymphocytosis (MBL) are premalignant 
monoclonal B- cell disorders, the former 
progressing to myeloma at a rate of around 
1% per year1 2 and the latter to chronic 
lymphocytic leukaemia (CLL) at around 
2% per year.3 4 Diagnosed more frequently 
in men than women and people over 60 
years of age,5 6 overt symptoms of haemato-
logical malignancy are, by definition, absent 
in both MBL and MGUS.7 Accordingly, 
although some premalignant disorders are 
found coincidentally during routine health 
checks, others are identified during diag-
nostic work- up investigations; MGUS during 
the course of tests applied to detect a range 
Strengths and limitations of this study
 ► Data are from an established population- based co-
hort within which all haematological malignancies 
and related clonal disorders are diagnosed, moni-
tored and coded at a single laboratory.
 ► Providing nationally generalisable data, all diagnoses 
are included, and complete follow- up is achieved via 
linkage to nationwide administrative datasets.
 ► The age- matched and sex- matched general popula-
tion cohort enables baseline activity and rate ratios 
to be calculated, both before and after premalignan-
cy detection.
 ► Analyses are constrained by the fact that hospital 
episodes statistics are primarily collected for admin-
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of potential conditions and illnesses8 9 and MBL during 
episodes of unexplained lymphocytosis.4 10
In addition to the association with haematological 
malignancy, individuals with MGUS or MBL sometimes 
experience higher than expected levels of mortality and 
morbidity that are independent of cancer.4 8 11–16 Indeed, 
although most individuals with these disorders suffer 
no obvious ill effects, interest in their relationship with 
other comorbidities has increased markedly in recent 
years, MBL largely in relation to its potential to impact on 
the immune response17 and MGUS due to the systemic 
organ and tissue damage that can be caused by mono-
clonal immunoglobulins secreted by the abnormal B- cell 
clone.18 Hitherto, however, most information about these 
associations has been derived either from case–control 
studies established to look at risk factors for disease devel-
opment (eg, family history of disease) and additional 
tests applied to specific patient groups (eg, patients with 
kidney disease) or cohort studies that track individuals 
with either MGUS or MBL forwards in time from their 
diagnosis.5 13 18 However, despite the undoubted interest 
in the sequence of health events, as far as we are aware, no 
systematic population- based investigations of the comor-
bidity patterns that precede and succeed a diagnosis of 
either MGUS or MBL have been undertaken in the same 
cohort.
With a view to shedding light on the health events 
occurring before and after the diagnosis of MGUS and 
MBL, the present report uses data from an established UK 
population- based patient cohort of haematological malig-
nancies and related disorders to examine the comorbidity 
patterns of individuals with these premalignancy clonal 
disorders (MGUS=2193, MBL=561). To enable effect 
size quantification, these patterns are compared with the 
baseline activity of an individually age- matched and sex- 
matched (10 per patient) general population comparison 
cohort.
METHODS
Cases are from the Haematological Malignancy Research 
Network (HMRN; www. HMRN. org), a specialist UK 
registry established in 2004 to provide robust generalis-
able data to inform contemporary clinical practice and 
research across the country as a whole.19 20 HMRN oper-
ates under a legal basis that permits data to be collected 
directly from health records without explicit consent. Set 
within a catchment population of around four million 
that is served by 14 hospitals and has a socioeconomic 
profile which is broadly representative of the UK as a 
whole, all haematological cancers and related conditions 
are diagnosed and coded by clinical specialists at a single 
integrated haematopathology laboratory, the Haema-
tological Malignancy Diagnostic Service ( www. HMDS. 
info), using standardised diagnostic criteria and the latest 
WHO International Statistical Classification of Diseases 
third revision (ICD- O-3) classification.7 Specifically, in 
relation to the present report, which covers diagnoses 
made during 2009–2015, MBL was defined by a periph-
eral blood monoclonal B- cell count <5×109/L in individ-
uals with no other features of a B- cell lymphoproliferative 
disorder, in MGUS by a serum paraprotein less than 30 
g/L and in those where a bone marrow examination was 
considered necessary following clinical examination, a 
clonal bone marrow plasma cells/lymphoplasmacytic 
infiltration of less than 10%. Hence, within the HMRN 
region, as in other diagnostic settings,21 22 invasive bone 
marrow examinations in patients with MGUS are gener-
ally only carried when laboratory or clinical features 
are indicative of an underlying plasma cell neoplasm, 
lymphoproliferative disorder, monoclonal immunoglob-
ulin deposition disease (eg, amyloidosis) or conditions 
like polyneuropathy, organomegaly, endocrinopathy, 
monoclonal gammopathy and skin changes (POEMS) 
syndrome.7
To facilitate comparisons with unaffected individuals, 
HMRN also has a general population cohort. To create 
this ‘control’ cohort, all patients diagnosed during 2009–
2015 with a haematological malignancy or related clonal 
disorder (n=18 127) were individually matched on sex 
and age at the point of diagnosis to 10 randomly selected 
individuals from the same catchment population. All 
controls were assigned a serial number that linked them 
to their matched case and a ‘pseudodiagnosis’ date that 
corresponded to their matched case’s diagnosis date. 
Individuals in the patient cohort and the comparison 
cohort are linked to the same nationwide information on 
deaths, cancer registrations and Hospital Episode Statis-
tics (HES). At the point of selection and matching, all 
controls were resident in the HMRN region and none 
had a previous cancer registration for a haematological 
malignancy.23 24 Hence, for the control cohort (in contrast 
to the patient cohort) no additional health information 
outside that contained within national administrative 
datasets was available.
Using similar methods to those previously described,23–25 
associations with hospital inpatient activity (HES admitted 
patient care) and outpatient activity (HES outpatient 
(HES- OP)) in the 5 years prior to diagnosis/pseudodiag-
nosis through to the 3 years after diagnosis were investi-
gated. HES inpatient data contain ICD-10 codes derived 
from discharge summaries26 and associations with these 
were examined in relation to the 17 specific conditions 
in the Charlson Comorbidity Index.27–29 By contrast, 
HES- OP data contain details about the type of outpa-
tient attendance, the majority being linked to consultant 
specialty codes (eg, ophthalmology, rheumatology), with 
the remainder largely comprising routine follow- up/
monitoring, nurse- led clinic attendances (eg, anticoagu-
lant clinics) and consultations with allied health profes-
sionals (eg, podiatry).
This report includes all patients (cases) who were newly 
diagnosed with either MGUS (n=2193) or MBL (n=561) 
between 1 January 2009 and 31 December 2015 and their 
matched controls (n=27 538); individuals diagnosed with 
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MBL diagnosis were considered ineligible. All cases and 
controls were followed up for cancer registration and 
death until March 2017 and hospital activity (inpatient 
and outpatient) until March 2016. Additionally, progres-
sions and/or transformations among cases were identified 
through HMDS up to March 2017. Data were summarised 
using standard methods. Overall survival, hospital activity 
and rate ratios (RRs) were calculated using time- to- event 
analyses. The Stata program ‘strel’ was used to estimate 
relative survival (RS), using age- specific and sex- specific 
background mortality rates from national life tables.30 31 
All analyses were conducted using Stata V.16.0.
Patient and public involvement (PPI)
PPI is integral to HMRN and takes place via a dedi-
cated patient partnership, overseen by a lay committee. 
Patients from the partnership are involved in identifying 
key research questions and participate in all our funding 
applications. Furthermore, patients and their relatives 
routinely take part in the dissemination of HMRN’s 
Table 1 Characteristics of patients diagnosed with monoclonal gammopathy of undetermined significance (MGUS) or 










Total 2193 (100) 21 928 (100) 561 (100) 5610 (100)
Gender
  Male 1131 (51.6) 10 620 (48.4) 328 (58.5) 3280 (58.5)
  Female 1062 (48.4) 11 308 (51.6) 233 (41.5) 2330 (41.5)
Age (years)
  <60 347 (15.8) 3470 (15.8) 85 (15.2) 850 (15.2)
  60–70 500 (22.8) 5000 (22.8) 153 (27.3) 1530 (27.3)
  70–80 782 (35.7) 7820 (35.7) 194 (34.6) 1940 (34.6)
  ≥80 564 (25.7) 5638 (25.7) 129 (23.0) 1290 (23.0)
  Median (IQR) 73.4 (64.6–80.2) 73.4 (64.6–80.2) 72.1 (64.5–79.2) 72.1 (64.5–79.2)
Overall survival*
  5 years (95% CI) 71.9 (69.5 to 74.1) 80.1 (79.4 to 80.7) 77.2 (72.5 to 81.2) 80.7 (79.4 to 81.9)
Relative survival
  5 years (95% CI) 90.2 (87.4 to 92.4) 99.5 (98.7 to 99.8) 94.3 (86.3 to 97.7) 98.5 (96.8 to 99.3)
Progressions and transformations*
  Total 75 (3.4) 140 (25.0)
  Myeloma 48 (2.2) – – –
  CLL† 1 (0.05) – 137 (24.4) –
  Other 26 (1.2) – 3 (0.5) –
Non- haematological cancer registrations*
  Total 185 (8.4) 1748 (8.0) 58 (10.3) 494 (8.8)
  Lung 31 (1.5) 190 (0.9) 4 (0.7) 59 (1.1)
  Prostate‡ 20 (1.8) 178 (1.6) 3 (0.9) 56 (1.7)
  Colorectal 19 (0.9) 166 (0.8) 6 (1.1) 40 (0.7)
  Breast‡ 15 (1.4) 135 (1.3) 4 (1.7) 16 (0.7)
Comorbidity score before MGUS/MBL 
diagnosis§
  0 1256 (57.3) 15 893 (72.5) 419 (74.7) 4115 (73.4)
  1 506 (23.1) 3617 (16.5) 84 (15.0) 898 (16.0)
  ≥2 431 (19.7) 2418 (11.0) 58 (10.3) 597 (10.6)
  p<0.001 p=0.78
*Followed up until 15 March 2017.
†Chronic lymphocytic leukaemia (CLL).
‡Prostate for men only, breast for women only.
§≥1 hospital admission with a diagnosis of 1 of the 17 conditions included in the Charlson Comorbidity Index25–27 during the 5 years to 1 month 
before MGUS/MBL diagnosis (patients)/pseudodiagnosis (controls).
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findings, which also occurs via our project website: www. 
yhhn. org.
RESULTS
Characteristics of individuals with either MGUS or MBL 
are summarised alongside their corresponding controls 
in table 1. Both MGUS and MBL were more commonly 
diagnosed in males (51.6% MGUS, 58.5% MBL) and indi-
viduals over the age of 70 years (median diagnostic age 
73.4 years for MGUS and 72.1 years for MBL). At 90.2% 
(95% CI 87.4% to 92.4%), the 5- year RS of patients diag-
nosed with MGUS was significantly lower (p<0.01) than 
that of their general population controls (RS 99.5%, 95% 
CI 98.7% to 99.8%). For MBL, the difference was far 
less marked, the 5- year RS being 94.3% (95% CI 86.3% 
to 97.7%) for MBL cases and 98.5% (95% CI 96.8% to 
99.3%) for their controls. Interestingly, the observed vari-
ations in blood cancer progression were in the opposite 
direction to those seen for mortality: 75 (3.4%) patients 
with MGUS were diagnosed with a haematological 
malignancy (48/75 were myelomas) before April 2017, 
compared with 140 (25.0%) patients with MBL (137/140 
were CLLs). No significant differences were, however, 
evident for non- haematological cancer registrations, 
although the frequencies were slightly higher for MGUS 
(8.4%) and MBL (10.3%) than for their corresponding 
controls (8.0% and 8.8%, respectively).
With respect to comorbidity, in the years leading up 
to diagnosis, patients with MGUS were significantly 
more likely than their corresponding controls to have 
Figure 1 Inpatient (IP) and outpatient (OP) monthly hospital visit activity rates 5 years before to 3 years after diagnosis (cases)/
pseudodiagnosis (controls) excluding haematology attendances. (A) Monoclonal gammopathy of undetermined significance 
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a record of at least 1 of the 17 comorbidities specified 
in the Charlson Comorbidity Index27–29 recorded in 
their discharge summaries, but no differences between 
MBL cases and their controls were evident (table 1). 
More information about hospital activity patterns of 
cases with MGUS/MBL and their general population 
controls is shown in figure 1, which shows inpatient and 
outpatient activity (excluding haematology) during the 
5 years before and the 3 years after diagnosis of MGUS 
(figure 1A) and MBL (figure 1B). In the period before 
diagnosis, patients with MGUS (figure 1A) had consis-
tently higher outpatient activity rates than their controls, 
the disparity increasing markedly during the 18 months 
leading up to the formal diagnosis of MGUS by haemato-
pathology where it remained high for about 12 months, 
before gradually falling and levelling out at a higher 
level than before diagnosis. Although less pronounced, a 
similar pattern is evident in inpatient data. With smaller 
numbers and more scatter, variations in outpatient and 
inpatient activity in MBL are less evident (figure 1B).
Figure 2 shows outpatient attendance frequencies (at 
least two specialty- specific visits) in the 3 years before and 
in the 3 years after MGUS diagnosis for the top 25 clin-
ical specialties, visits within 1 month (±) of diagnosis/
pseudodiagnosis are excluded. As is evident from the 
plot, the increased outpatient activity seen among cases 
(figure 1) occurs across a range of clinical specialties, the 
highest frequencies occurring in ophthalmology, haema-
tology, general surgery, orthopaedics, general (internal) 
medicine and rheumatology. However, excluding haema-
tology where, as expected, attendances increased mark-
edly just before and after MGUS diagnosis, the largest 
RRs both before (figure 3A) and after (figure 3B) diag-
nosis were for nephrology (before diagnosis RR=4.29, 
95% CI 3.90 to 4.71; after diagnosis RR=13.8, 95% CI 12.8 
to 15.0) and rheumatology (before diagnosis RR=3.40, 
95% CI 3.18 to 3.63; after diagnosis RR=5.44, 95% CI 
5.08 to 5.83). Other significant associations (p<0.05) with 
RR point estimates above 2.0 were evident for endocri-
nology, neurology and respiratory medicine, as well as 
for the nurse- led monitoring activities which form part of 
ongoing clinical care across a range of specialties.
MGUS data are stratified by subtype in table 2. 
Accounting for around two- thirds of the total (n=1471; 
67.0%), the IgG subtype dominates, followed by IgM 
(n=350; 16.0%) and IgA (n=266; 12.1%). The remaining 
106 (4.8%) ‘other’ category comprise a mix of subtypes: 
light chain only (n=60), IgG+IgM (n=17), IgG+IgA (n=6), 
IgA+IgM (n=1), IgE (n=2) and not recorded (n=20). As 
expected, progression to myeloma in the 3 years following 
MGUS diagnosis was largely restricted to the IgG and IgA 
subtypes. The age distributions, 5- year survival estimates 
(overall and relative) and non- haematological malig-
nancy frequencies of the main subtypes were broadly 
similar, although patients in the combined ‘other’ cate-
gory tended to be slightly older and to fare less well 
(RS=77.6%, 95% CI 62.6% to 87.2%). The numbers 
of patients in the individual groups were, however, too 
Figure 2 Percentage of cases and controls with at least two specialty- specific outpatient visits in the 3 years before and after 
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sparse to examine the data in greater depth. Finally, 
during the study period (2009–2015), in addition to the 
detection of a paraprotein in peripheral blood, around 
70% (1527/2193) of patients with MGUS in our cohort 
had a confirmatory bone marrow examination taken to 
exclude an underlying neoplasm. The patient character-
istics and secondary care activity patterns of those who 
had bone marrow examinations were, however, broadly 
similar to those who did not (data not shown).
DISCUSSION
Including data on nearly 3000 cases with premalignant 
clonal disorders and 10 times as many age- matched and 
sex- matched general population controls, this large UK 
record- linkage study found that individuals with MGUS 
not only experienced excess mortality and morbidity after 
diagnosis, but also excess morbidity in the 5 years before 
diagnosis. By contrast, only marginal increases in mortality 
and morbidity were evident for MBL, none of which were 
consistent or varied significantly from the general popu-
lation. Interestingly, progression patterns were in the 
opposite direction: in the years following detection of a 
premalignant clonal disorder, 3.4% (n=75/2193) of those 
with MGUS developed a haematological malignancy (48 
of which were myelomas) before April 2017, compared 
with 25.0% (n=140/561) of those with MBL (137 of which 
were CLLs).
The elevated mortality and morbidity following a diag-
nosis of MGUS, which seems largely independent of 
progression to cancer, is consistent with reports relating 
to the potential clinical significance of this disorder.11–18 
Corresponding to the period of diagnostic work- up, 
our data also demonstrate the pronounced increase in 
hospital activity in the months surrounding MGUS diag-
nosis, the highest activity being observed in the 6 months 
before and 6 months after diagnosis. Of more impor-
tance, perhaps, the analyses clearly show that hospital 
activity in people subsequently diagnosed with MGUS 
is often elevated many years before diagnosis: excesses 
being observed in specialties covering most organ and 
tissue systems including nephrology, endocrinology, 
neurology, rheumatology, gastroenterology, dermatology 
Figure 3 Monthly outpatient attendance rates (per 100 persons) in cases and controls and rate ratios by outpatient specialty 






















































































































































































Table 2 Characteristics of patients diagnosed with monoclonal gammopathy of undetermined significance (MGUS) and their corresponding controls, stratified by MGUS 
subtype:HMRN diagnoses 2009–2015
MGUS subtype

















Total 1471 (100.0) 14 709 (100.0) 350 (100.0) 3499 (100.0) 266 (100.0) 2660 (100.0) 106 (100.0) 1060 (100.0)
Gender
  Male 745 (50.6) 7449 (50.6) 177 (50.6) 1769 (50.6) 145 (54.5) 1450 (54.5) 64 (60.4) 640 (60.4)
  Female 726 (49.4) 7260 (49.4) 173 (49.4) 1730 (49.4) 121 (45.5) 1210 (45.5) 42 (39.6) 420 (39.6)
Age (years)
  <60 239 (16.2) 2390 (16.2) 50 (14.3) 500 (14.3) 48 (18.0) 480 (18.0) 10 (9.4) 100 (9.4)
  60–70 336 (22.8) 3360 (22.8) 80 (22.9) 800 (22.9) 56 (21.1) 560 (21.1) 28 (26.4) 280 (26.4)
  70–80 514 (34.9) 5140 (34.9) 130 (37.1) 1300 (37.2) 104 (39.1) 1040 (39.1) 34 (32.1) 340 (32.1)
  ≥80 382 (26.0) 3819 (26.0) 90 (25.7) 899 (25.7) 58 (21.8) 580 (21.8) 34 (32.1) 340 (32.1)
  Median 73.4 73.4 73.0 73.0 73.0 73.0 75.3 75.3
Survival 5 years (95% CI)†
  Overall 72.3 (69.4 to 74.9) 79.5 (78.7 to 80.3) 69.6 (63.3 to 75.0) 81.3 (79.7 to 82.9) 74.2 (67.3 to 79.8) 82.4 (80.6 to 84.1) 68.6 (56.5 to 78.0) 77.6 (74.1 to 80.7)
  Relative 90.6 (86.9 to 93.2) 99.2 (98.3 to 99.7) 84.2 (75.8 to 89.8) 99.3 (93.7 to 99.9) 88.3 (78.5 to 93.8) 98.5 (95.3 to 99.5) 77.6 (62.6 to 87.2) 96.8 (89.5 to 99.1)
Progressions/transformations†
  Total 44 (3.0) – 8 (2.3) – 17 (6.4) – 6 (5.7) –
  Myeloma 34 (2.3) – 1 (0.3) – 11 (4.1) – 2 (1.9) –
  Other 10 (0.7) – 7 (2.0) – 6 (2.3) – 4 (3.8) –
Non- haematological cancer registrations†
  Total 118 (8.0) 1173 (8.0) 41 (11.7) 277 (7.9) 19 (7.1) 210 (7.9) 7 (6.6) 88 (8.4)
  Lung 16 (1.1) 133 (0.9) 6 (1.7) 24 (0.7) 4 (1.5) 21 (0.8) 5 (4.7) 12 (1.1)
  Prostate‡ 14 (1.9) 115 (1.5) 3 (1.7) 27 (1.5) 3 (2.1) 25 (1.7) – 11 (1.7)
  Colorectal 16 (1.1) 112 (0.8) 2 (0.6) 26 (0.7) 1 (0.4) 20 (0.7) – 8 (0.8)
  Breast‡ 9 (1.2) 88 (1.2) 4 (2.3) 26 (1.5) 2 (1.7) 15 (1.2) – 6 (1.4)
Hospital outpatient activity (≥3 visits), excluding haematology and visits within 1 month of diagnosis§
5 years before 
diagnosis
1173 (79.7) 9103 (61.9) 287 (82.0) 2155 (61.6) 216 (81.2) 1633 (61.4) 89 (84.0) 663 (62.5)
3 years after 
diagnosis
964 (65.5) 6558 (44.6) 240 (68.6) 1577 (45.1) 176 (66.2) 1154 (43.4) 70 (66.0) 445 (42.0)
*Biclonal, IgD, IgE, light chain, not known.
†Followed up until 15 March 2017.
‡Prostate for men only, breast for women only.
§In the 5 years before diagnosis/pseudodiagnosis and 3 years after diagnosis/pseudodiagnosis.
HMRN, Haematological Malignancy Research Network.
Protected by copyright.
 on February 23, 2021 at The Librarian J B Morrell Library. http://bmjopen.bmj.com/ BMJ Open: first published as 10.1136/bmjopen-2020-041296 on 22 February 2021. Downloaded from 
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and respiratory medicine. By contrast, although hospital 
activity increased in the months around the time of MBL 
diagnosis, no consistent differences or patterns either 
before or after the diagnosis were detected. Furthermore, 
in agreement with findings reported in other studies that 
used age- matched and sex- matched controls, no associa-
tions with mortality were detected.3 32 However, given the 
fact that MBL has been associated with increased suscepti-
bility to infection and non- CLL related mortality,4 15 33 it is 
possible that the findings relating to subsequent morbidity 
and mortality could change as our data mature, length 
of follow- up increases and linkage to primary care data 
becomes possible.
The age and sex distributions of our population- based 
cohorts are broadly similar to those of other published 
MBL3 34 35 and MGUS1 2 11 series, as is the dominance of 
the IgG MGUS subtype.1 2 Providing nationally general-
isable data, additional strengths of our study include its 
large well- defined population, within which all haema-
tological malignancies and related clonal disorders are 
diagnosed, monitored and coded using up- to- date stan-
dardised procedures at a central haematopathology labo-
ratory.19 In this context, it is important to bear in mind 
that most people with premalignant clonal disorders 
remain asymptomatic and that our cohorts contain a 
relatively large proportion of people who came to clin-
ical attention in primary and/or secondary care and 
were referred to haematology for further investigation. 
More specifically, around 98% of patients in our MBL 
cohort had high- count MBL, and within the HMRN 
region, patients with MBL are monitored routinely using 
flow cytometry so laboratory progressions (B- cell count 
>5×109/L) may be detected with higher sensitivity than 
in cases monitored clinically. This is supported by the 
fact that over the follow- up period (median 3.8 years), 
around a quarter of patients with MBL progressed to CLL 
and 3.6% required treatment. Prevalence comparisons 
with population screening studies also confirm that the 
majority of those over 50 years of age with monoclonal 
immunoglobulin in their blood/urine would not be 
included in our MGUS cohort.5 20 35–37 In this context, 
it is important to remember that some members of the 
control cohort would, if screened, have had a prema-
lignant clonal disorder detected in their peripheral 
blood.13 32 33 38 39 Unfortunately, however, information 
on diagnostic work- up tests and monitoring procedures 
is not routinely included in nationally compiled HES. 
Furthermore, the anonymised nature of the control 
cohort means that individuals cannot be linked to other 
data sources. Hence, although we know that members 
of the control cohort had no prior record of an MGUS 
or MBL diagnosis within the study region in the years 
leading up to their corresponding case’s diagnosis, we do 
not know how many people developed these conditions 
after their case was diagnosed.
The diversity of morbidity effects seen among individ-
uals with MGUS is consistent with the expanding body 
of evidence relating to the potential adverse impact 
that even low levels of circulating monoclonal protein 
(M- protein) can have. Thus far, the complex under-
pinning mechanisms identified include: deposition of 
M- protein aggregations of varying immunoglobulin 
subtypes in different organs as well as the induction of 
autoantibodies and cytokines that can have an impact on 
organs and tissues in a variety of deleterious ways.13 18 40 41 
Indeed, the recognised number of M- proteinmediated 
entities is increasing, with several affecting multiple 
organs; well- known deposition syndromes including 
primary amyloidosis and paraneoplastic conditions such 
as POEMS syndrome.7 42 As evidenced in our analysis, 
kidney involvement is frequent, both in the years before 
(fourfold excess) and after (14- fold excess) MGUS diag-
nosis. Indeed, the umbrella term monoclonal gammop-
athy of renal significance has recently been suggested to 
cover all M- protein- mediated kidney disorders that fail 
to meet the diagnostic criteria for multiple myeloma or 
any other B- cell malignancy.13 18 43 Other organ- specific 
terms continue to emerge, and with a view to improving 
recognition of these complex disorders which clearly 
pose significant diagnostic and treatment challenges, the 
overarching term monoclonal gammopathy of clinical 
significance has also been suggested.18
From a haematological malignancy perspective, MGUS 
and MBL are generally considered to be relatively benign 
conditions. However, both can have other deleterious 
health consequences, the effect of monoclonal gammop-
athy being particularly striking. Impacting significantly 
the survival and having the potential to cause systemic 
disease and wide- ranging damage to most organs and 
tissues, the adverse outcomes associated with the M- pro-
teins produced by the abnormal B- cell clone can be severe 
and extend over many years. Even though most people 
with monoclonal immunoglobulins never develop a B- cell 
malignancy or suffer from any other form of M- protein- 
related organ/tissue- related disorder, the consequences 
for those that do can be extremely serious. In this regard, 
early targeting of pathogenic B- cell clones could miti-
gate both cancer and non- cancer effects, but currently, 
although knowledge is increasing, there is no known way 
to reliably identify such clones in the absence of other 
signs/symptoms. Hence, population screening cannot 
be recommended and diagnosis remains reliant on clin-
ical suspicion. However, the long- standing nature of the 
comorbidity associations seen prior to MGUS diagnosis in 
our data suggest that there may be room for improvement 
and that the implementation of strategies to improve 
awareness and earlier detection, as well as monitoring of 
high- risk patient groups, could prove beneficial.
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